Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization

被引:41
作者
Soares, Maria [1 ]
Madeira, Sara [1 ]
Correia, Jorge [1 ]
Peleteiro, Maria [1 ]
Cardoso, Fatima [2 ]
Ferreira, Fernando [1 ]
机构
[1] Univ Lisbon, CIISA, Fac Vet Med, P-1699 Lisbon, Portugal
[2] Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
关键词
Feline mammary carcinoma; Immunohistochemistry; Molecular subtype; Luminal B; Triple negative; Cancer model; BREAST-CANCER CLASSIFICATION; BASAL-LIKE SUBTYPE; PROGNOSTIC FACTORS; ESTROGEN-RECEPTOR; TUMOR; EXPRESSION; SURVIVAL; CANINE; MODEL; INDEX;
D O I
10.1016/j.breast.2016.02.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Molecular classification of feline mammary carcinomas (FMC) from which specific behavioral patterns may be estimated has potential applications in veterinary clinical practice and in comparative oncology. In this perspective, the main goal of this study was to characterize both the clinical and the pathological features of the different molecular phenotypes found in a population of FMC (n = 102), using the broadly accepted IHC-based classification established by St. Gallen International Expert Consensus panel. The luminal B/HER2-negative subtype was the most common (29.4%, 30/102) followed by luminal B/HER2-positive subtype (19.6%, 20/102), triple negative basal-like (16.7%, 17/102), luminal A (14.7%, 15/102), triple negative normal-like (12.7%, 13/102) and finally, HER2-positive subtype (6.9%, 7/102). Luminal A subtype was significantly associated with smaller tumors (p = 0.024) and with well differentiated ones (p < 0.001), contrasting with the triple negative basal-like subtype, that was associated with larger and poorly differentiated tumors (p < 0.001), and with the presence of necrotic areas in the tumoral lesion (p = 0.003). In the survival analysis, cats with Luminal A subtype presented the highest survival time (mean OS = 943.6 days) and animals with triple negative basal-like subtype exhibited the lowest survival time (OS mean = 368.9 days). Moreover, two thirds (64%, 32/50) of the queens with multiple primary tumors showed different molecular subtypes in each carcinoma, revealing that all independent lesions should be analyzed in order to improve the clinical management of animals. Finally, the similarities between the subtypes of feline mammary tumors and human breast cancer, reveal that feline can be a valuable model for comparative studies. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:44 / 51
页数:8
相关论文
共 54 条
[1]   EXPRESSION OF ER/PR/HER2, BASAL MARKERS AND ADHESION MOLECULES IN PRIMARY BREAST CANCER AND IN LYMPH NODES METASTASES: A COMPARATIVE IMMUNOHISTOCHEMICAL ANALYSIS [J].
Adamczyk, Agnieszka ;
Niemiec, Joanna ;
Ambicka, Aleksandra ;
Malecki, Krzysztof ;
Wysocki, Wojciech H. ;
Mitus, Jerzy ;
Rys, Janusz .
POLISH JOURNAL OF PATHOLOGY, 2012, 63 (04) :228-234
[2]   Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research [J].
Bosch, Ana ;
Eroles, Pilar ;
Zaragoza, Rosa ;
Vina, Juan R. ;
Lluch, Ana .
CANCER TREATMENT REVIEWS, 2010, 36 (03) :206-215
[3]   Molecular Phenotype in Mammary Tumours of Queens: Correlation between Primary Tumour and Lymph Node Metastasis [J].
Brunetti, B. ;
Asproni, P. ;
Beha, G. ;
Muscatello, L. V. ;
Millanta, F. ;
Poli, A. ;
Benazzi, C. ;
Sarli, G. .
JOURNAL OF COMPARATIVE PATHOLOGY, 2013, 148 (2-3) :206-213
[4]   Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions [J].
Burrai, Giovanni P. ;
Mohammed, Sulma I. ;
Miller, Margaret A. ;
Marras, Vincenzo ;
Pirino, Salvatore ;
Addis, Maria F. ;
Uzzau, Sergio ;
Antuofermo, Elisabetta .
BMC CANCER, 2010, 10
[5]   Invasive breast cancer: a significant correlation between histological types and molecular subgroups [J].
Caldarella, A. ;
Buzzoni, C. ;
Crocetti, E. ;
Bianchi, S. ;
Vezzosi, V. ;
Apicella, P. ;
Biancalani, M. ;
Giannini, A. ;
Urso, C. ;
Zolfanelli, F. ;
Paci, E. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (04) :617-623
[6]   Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].
Cheang, Maggie C. U. ;
Chia, Stephen K. ;
Voduc, David ;
Gao, Dongxia ;
Leung, Samuel ;
Snider, Jacqueline ;
Watson, Mark ;
Davies, Sherri ;
Bernard, Philip S. ;
Parker, Joel S. ;
Perou, Charles M. ;
Ellis, Matthew J. ;
Nielsen, Torsten O. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750
[7]   New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance [J].
Curigliano, Giuseppe .
CANCER TREATMENT REVIEWS, 2012, 38 (04) :303-310
[8]  
de las Mulas J.M., 2000, Rev Oncologia, V2, P274, DOI DOI 10.1007/BF02979590
[9]  
De Maria R, 2005, CANCER RES, V65, P907
[10]   Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer [J].
Edwards, Brenda K. ;
Noone, Anne-Michelle ;
Mariotto, Angela B. ;
Simard, Edgar P. ;
Boscoe, Francis P. ;
Henley, S. Jane ;
Jemal, Ahmedin ;
Cho, Hyunsoon ;
Anderson, Robert N. ;
Kohler, Betsy A. ;
Eheman, Christie R. ;
Ward, Elizabeth M. .
CANCER, 2014, 120 (09) :1290-1314